Dyne Therapeutics, Inc.

DYNNASDAQHealthcare● Active

$16.81

$-0.23(-1.35%)

Market Cap$2.8B

P/E Ratio—

52W High$25

52W Low$8.06

Avg Volume1.9M

Open$17.28

Beta1.08

Overview

Dyne Therapeutics, Inc. (DYN) Free Cash Flow & Analysis

Annual & trailing free cash flow, FCF margin, YoY change, valuation ratios, and peer context.

DYN · free cash flow · updated Jun 8, 2026

Core FCF metrics

DYN · FCF · TTM · margin & CAGR

Free cash flow was −$405.1M for FY2025 (fiscal year ending 2025-12-31), down 37.4% year-over-year

FY2025 Free Cash Flow−$405.1M▼ -37.4% YoY

Trailing 12M (TTM)−$462.2Mtrailing 4 quarters sum

FCF Margin——

3-Year CAGRN/AN/A — contains negative FCF

5-Year CAGRN/AN/A — contains negative FCF

FormulaFCF = Operating Cash Flow − Capital ExpendituresTTM = trailing 4 quarters sumCAGR → N/A if either endpoint ≤ 0

Source: FMP /cash-flow-statement · SEC 10-K / 10-Q · USDUpdated: Jun 8, 2026

Annual free cash flow history

FCF ($B, upper) · YoY Growth % (lower)

Positive FCFNegative FCF

Free Cash Flow

YoY Growth %

Annual free cash flow data

DYN · free cash flow history · annual / quarterly

Fiscal YearOperating CFCapExFree Cash FlowYoY ChangeFCF Margin

FY2025Latest−$403.2M(2M)−$405.1M▼ 37.4%—

FY2024−$292.4M(2M)−$294.7M▼ 56.0%—

FY2023−$188.2M(1M)−$188.9M▼ 20.5%—

FY2022−$153.6M(3M)−$156.7M▼ 27.2%—

FY2021−$119.6M(4M)−$123.2M▼ 158.4%—

FCF = Operating Cash Flow − Capital Expenditures · CapEx shown as (negative) · Source: SEC filings via FMP

FCF valuation metrics

DYN · P/FCF · FCF yield · FCF per share

Dyne Therapeutics, Inc. (DYN) reported negative free cash flow of −$0.41B. FCF-based valuation ratios are not meaningful when FCF is negative.

FCF Yield (TTM)

N/A

Free Cash Flow ÷ Market Cap

per FMP freeCashFlowYieldTTM definition

FCF per Share (TTM)

N/A

TTM FCF ÷ Shares Outstanding

Price / FCF

N/A

Share Price ÷ FCF per Share

EV / FCF (TTM)

N/A

Enterprise Value basis

FCF-based valuation ratios are only meaningful when free cash flow is positive. Negative FCF indicates capital expenditures exceeded operating cash flow.

Source: FMP /key-metrics-ttm · /cash-flow-statement Q · /income-statementFY2025 · 2025-12-31

Cash flow statement summary

DYN · cash flow statement · operating / investing / financing

For FY2025, Dyne Therapeutics, Inc. generated −$403.2M in operating cash flow and spent 2M in capital expenditures, yielding −$405.1M in free cash flow.

Operating Activities

−$403.2M

Cash from core business operations

2025-12-31

Investing Activities

−$28.8M

CapEx, acquisitions & investments

2025-12-31

Financing Activities

+$890.3M

Buybacks, dividends & debt

2025-12-31

FCF FormulaOperating CF (−$403.2M) − |CapEx| (2M) = FCF (−$405.1M)

For the complete Operating / Investing / Financing line-item breakdown:

View Full Cash Flow Statement →

Free cash flow vs peers (Healthcare)

DYN vs peers · FCF

#CompanyFree Cash FlowYoYFCF MarginRelative

Dyne Therapeutics, Inc.YOU

DYN

−$405.1M-37.4%—

Loss

UnitedHealth Group Incorporated

UNH

$16.07B-22.4%3.6%

82%

Eli Lilly and Company

LLY

$8.97B+2065.6%13.8%

46%

Healthcare · Sorted by FCF · FMP /cash-flow-statementFull FCF Rankings →

About Free Cash Flow & Methodology

Dyne Therapeutics, Inc. (DYN) reported free cash flow of −$405.1M for FY2025 (fiscal year ending 2025-12-31), down 37.4% year-over-year.

Based on available data, Dyne Therapeutics, Inc. has maintained positive free cash flow for at least 3 fiscal year(s). FCF peaked at $361.0M in FY2017.

Data sourced from FMP /cash-flow-statement · SEC 10-K / 10-Q · USD.

Q&A and summaries align with SEC 10-K/10-Q cash flow disclosures and FMP /cash-flow-statement where noted.

Revenue Financial statements Net income Earnings Forecast Price history Market cap Cash on hand P/E ratio

Frequently asked questions

DYN free cash flow · 8 questions

Dyne Therapeutics, Inc. free cash flow was −$405.1M for FY2025, down 37.4% year-over-year. On a trailing twelve-month (TTM) basis, free cash flow stands at −$462.2M.

DYN free cash flowDYN FCFDYN FCF 2025DYN free cash flow TTM

▸ Source: FMP /cash-flow-statement · US GAAP · Dyne Therapeutics, Inc. · Dyne Therapeutics, Inc. SEC 10-K & 10-Q filings · US GAAP · Last updated: Jun 8, 2026